OBJECTIVE: To provide a preliminary assessment of the efficacy and safety of @entity35787 treatment of @entity5815 . DESIGN: A placebo-controlled, double-blind, random-allocation crossover trial of 6 weeks of @entity7842 . SETTING: An outpatient clinical trials unit. @entity1 : Twenty-five @entity1 with @entity5815 (mean age, 40 years; 19 [76%] @entity1 ; mean duration of illness, 7.0 years) were recruited from a research and clinic registry. Five @entity1 withdrew from the trial. INTERVENTIONS: All @entity1 were scheduled to receive @entity35787 (0.1-0.2 mg) or a placebo for 6 weeks in each treatment. MAIN OUTCOME MEASURES: Self-administered questionnaires were completed at the beginning and end of each treatment arm that asked @entity1 to rate the severity of their symptoms on a visual analogue scale. The Medical Outcomes Study 36-Item Short-Form Health Survey, a reaction time test, and a treadmill exercise test were used to assess functional status. Blood pressure, heart rate, and plasma @entity1063 levels were obtained at baseline. Blood pressure and heart rate were recorded at the end of the exercise test and monitored at all subsequent visits. RESULTS: At baseline, the study @entity1 reported symptom severity greater than 5 for most symptoms, and all had evidence of marked @entity73 . No improvement was observed in the severity of any symptom or in any test of function for the 20 @entity1 who completed both arms of the trial. Blood pressure and heart rate readings were unaffected by treatment, and plasma @entity1063 levels did not differ from those of a healthy control group. The incidence of adverse experiences was similar in the @entity7842 and placebo arms of the trial. CONCLUSION: Low-dose @entity7842 does not provide sufficient benefit to be evident in a preliminary blinded trial of unselected @entity1 with @entity5815 .

A preliminary placebo-controlled crossover trial of XXXX for @entity5815 .

@entity1 :: ('9606', 'Species') :: ['participants', 'women', 'patients', 'PATIENTS'] @entity73 :: ('MESH:D003072', 'Disease') :: ['functional impairments'] @entity35787 :: ('MESH:C034635', 'Chemical') :: ['fludrocortisone acetate'] @entity5815 :: ('MESH:D015673', 'Disease') :: ['chronic fatigue syndrome'] @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine'] @entity7842 :: ('MESH:D005438', 'Chemical') :: ['fludrocortisone']
@entity7842 :: (MESH:D005438,Chemical) :: ['fludrocortisone']
